Spanish Oncology Start-Up Ona Raises €30m
Aims To Be In The Clinic by 2023
Executive Summary
A syndicate of high-profile investors are backing the Barcelona-based firm's bid to develop biologics targeting metastatic-initiating cells and lipid metabolism.
You may also be interested in...
Spain’s SpliceBio Defies Sentiment With €50m Financing
The Barcelona-based firm, which has a protein splicing platform that aims to address the major limitation of delivering large genes using AAV vectors, has sealed the largest series A fundraising by a Spanish biotech.
More Spanish Biotechs To Benefit From Ysios Backing
Spain now enjoys a reasonable level of venture capital to help translate its scientific excellence into budding biotechs and the country's major life sciences backer Ysios is looking to unearth more jewels there, as well as in the rest of Europe and North America.
Fund+ Makes Moves In Europe With Further Growth On The Cards
In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.